
Hodgkin Lymphoma 2025 UPDATE
Two Onc Docs
00:00
Advanced‑stage updates: immunotherapy upfront
Discussion of stage III–IV: historical ABVD approach and 2025 options including nivolumab‑AVD and brentuximab regimens.
Play episode from 10:15
Transcript


